Clinical Trial Update: Atezolizumab in Combination With Bevacizumab, Carboplatin and Pemetrexed for EGFR-mutant Metastatic NSCLC Patients After Failure of EGFR Tyrosine Kinase Inhibitors [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating atezolizumab with bevacizumab, carboplatin, and pemetrexed for EGFR-mutant metastatic non-small cell lung cancer after EGFR TKI failure…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Atezolizumab (atezolizumab)
• Bevacizumab (bevacizumab)
• CARBOPLATIN (Carboplatin)
• Pemetrexed (pemetrexed)

Snippet

Sponsor: The University of Hong Kong | Conditions: NSCLC Stage IIIB, NSCLC Stage IV | Phase 2 | Status: UNKNOWN